A controversial clinical trial that planned to administer puberty blockers to transgender children has been dramatically halted over significant safety concerns, throwing the future of the research into serious doubt.
Regulatory Intervention Stops Planned April Start
The Department of Health and Social Care has paused the Pathways trial's planned April start date following direct intervention by the Medicines and Healthcare products Regulatory Agency. Some 226 children were due to receive drugs designed to halt their natural physical development as part of this investigation originally commissioned by Health Secretary Wes Streeting.
Safety Concerns Deemed 'Unacceptable'
This development comes after the Commission on Human Medicines declared puberty blockers posed "an unacceptable safety risk," leading Mr Streeting to impose an indefinite ban on their routine use. Despite this prohibition, the health secretary had supported the Pathways trial into side-effects, following recommendations from the Cass review examining treatment approaches for children experiencing gender distress.
The trial, led by researchers at King's College London, has faced mounting criticism regarding the ethics of administering drugs to children that could potentially cause irreversible harm to brain development and future fertility.
Scientific Dialogue to Address New Concerns
Discussions between the MHRA and trial researchers will commence next week to address the newly raised safety issues. The regulator has made clear that recruitment for the trial cannot begin until all concerns have been satisfactorily resolved. Notably, the MHRA has indicated it may seek to restrict participation to children aged fourteen and above, reflecting heightened caution regarding younger participants.
Charity Welcomes 'Immensely Relieved' Pause
Maya Forstater, chief executive of the sex-based rights charity Sex Matters, expressed profound relief at the regulatory intervention. "We are delighted and immensely relieved that the MHRA has pressed pause on the puberty blockers trial," she stated.
"This badly designed experiment would have harmed vulnerable children in the misguided effort to 'research' a treatment already known to offer no benefits and carry serious risk," Forstater continued. She highlighted what she described as "a complete failure of leadership and accountability" in the initial approval process.
Forstater praised the "grit and determination of clinicians and parents" who worked to highlight potential harms, adding: "We sincerely hope that all organisations involved will heed the MHRA's warning and that the trial will ultimately be cancelled."
She advocated instead for research focusing on outcomes for the approximately 2,000 young people who have already received puberty blockers.
Department Emphasises Safety as 'Driving Consideration'
A Department of Health and Social Care spokesperson reiterated that safety remained paramount: "We have always been clear about the red lines regarding this trial – ensuring the safety and wellbeing of the children and young people involved and always being led by the clinical evidence."
"The MHRA has now raised new concerns – directly related to the wellbeing of children and young people – and scientific dialogue will now follow with the trial sponsor," the spokesperson confirmed. "As the evidence is now being interrogated by clinicians, preparations for the trial have been paused."
The department emphasised that the trial would only proceed "if the expert scientific and clinical evidence and advice conclude it is both safe and necessary," adding that participant wellbeing "has always been the driving consideration."
Regulator Applies 'Highest Scrutiny'
An MHRA spokesperson explained their cautious approach: "With all complex clinical trials, MHRA's top priority is the safety and wellbeing of the trial participants. It is part of the usual process that clinical trials are kept continuously under review."
"The safety and wellbeing of the participants to be recruited into the PATHWAYS clinical trial is paramount, particularly in view of the age of the children and young people who may be involved," the regulator noted. "For this reason, the MHRA is applying the highest scrutiny and taking a cautious and measured approach."
The spokesperson confirmed that concerns "related to the wellbeing of participants" had been raised and that "scientific dialogue will now follow with the trial sponsor," with decisions based on "the best scientific evidence to ensure all trials are as safe as possible."
Legal Proceedings Potentially Affected
In a related development, the Department of Health and Social Care has shared the MHRA's correspondence with claimants considering a judicial review of the trial, requesting they pause legal proceedings while regulatory concerns are addressed. Puberty blockers, which are hormone-suppressing drugs designed to pause physical changes like facial hair growth and menstruation, remain at the centre of this heated medical and ethical debate.
